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Approximately 1,500 researchers, rep­
resenting more than 30 countries, 
attended the 70th Annual Meeting of 
the Society for Investigative Derma­
tology* to exchange information and 
ideas in the fields of dermatology and 
cutaneous biology. The nearly 900 
oral and poster presentations of both 
basic and clinical research on such 
diverse topics as microbial diversity, 
cell signaling, epidermal development, 
disease pathogenesis, translational 
medicine, immunology, viruses, and 
vaccines highlighted the diversity and 
advancement of the field of dermato­
logical research that is supported by the 
Society for Investigative Dermatology. 
The following discussion of selected 
research presentations from the meet­
ing illustrates not only the excellence 
in research in this field but also the 
breadth of information shared at this 
conference. We regret that, owing 
to space limitations, many excellent 
presentations are not mentioned here; 
however, meeting abstracts are available 
in print and online (J Invest Dermatol 
130 (Supplement 1), April 2010).
microbial diversity of human skin
Because humans are host to a variety of 
microorganisms that actually outnum­
ber human cells by a factor of 10, the 
bacterial flora of healthy human skin 
has been of interest to the dermatology 
community for quite some time, with 
descriptions published in the Journal of 
Investigative Dermatology as early as 
the 1950s. Although early reports were 
based on cultivatable species, current 
descriptions involve bacterial genom­
ic data based on sequences from the 
universal bacterial 16S rRNA gene. In 
fact, researchers are engaged in a proj­
ect to characterize the entire human 
microbiome (http://nihroadmap.nih.
gov/hmp) at multiple physiologic sites. 
Heidi Kong (National Institutes of 
Health, Bethesda, MD) discussed the 
microbiome with respect to community 
structure in both healthy and diseased 
skin. Interestingly, direct sequencing 
revealed much greater diversity and 
changes in the community structure 
compared with culture techniques. 
Together with her collaborators, Kong’s 
group analyzed skin swab, scrape, and 
punch samples from sebaceous, moist, 
and dry skin sites and found that spe­
cies richness was dependent on the 
skin site. Future studies using the high­
throughput 4­5­4 platform sequencing 
method are aimed at understanding 
how this community diversity changes 
with diseases, such as acne, atopic der­
matitis (AD), and psoriasis.
Employing similar techniques to 
investigate wound microbiology 
and pathogenesis, Anne Han (Johns 
Hopkins, Baltimore, MD) compared the 
microbial diversity of normal healthy 
skin and wounded skin. Because bac­
teria influence wound development, 
the composition of the communities 
present at these sites is of great interest 
for understanding the process. Again, 
metagenomic analysis of the 16S rRNA 
gene revealed higher diversity than did 
culture methods. Different community 
structures in healthy versus wounded 
skin were also found. Indeed, increased 
numbers of anaerobic species were 
found in biofilms in chronic wounds. 
Biofilms, which are aggregates of bac­
teria that are embedded in a self­secret­
ed matrix, actually impede treatment 
and wound healing. Furthermore, these 
bacteria were found to communicate 
via quorum­sensing molecules, which 
have been implicated in biofilm forma­
tion and regulation of virulence factors.
epidermal cell signaling
In an effort to understand the mecha­
nisms of organogenesis, Anthony Oro 
(Stanford University, Palo Alto, CA) 
presented evidence regarding sonic 
hedgehog (Shh) signaling–dependent 
hair morphogenesis in the hair fol­
licle epithelium and the mechanisms 
of concurrent prevention of tumori­
genesis, which occurs in response to 
increased Shh signaling. The primary 
cilium, which functions as a sensory 
organelle to transduce environmental 
signals to the nucleus, functions in hair 
follicle morphogenesis and regulates 
the Shh response. Shh components 
accumulate at the centrosome, which 
regulates cilia formation, and the end 
of the cilium actually binds Shh to pro­
mote signaling through this pathway. 
Missing in metastasis (MIM) is required 
for epithelial and mesenchymal Shh 
signaling and is also required for pri­
mary cilia formation. Loss of this factor 
resulted in a phenocopy of Shh signal­
ing loss. Endogenous MIM localized 
to the centrosome throughout the cell 
cycle, and the hMIM actin regulatory 
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domain rescued ciliogenesis in knock­
out systems, implicating actin in this 
process. Examination of the additional 
players cortactin (CTTN) and Src, which 
are required for cilia disassembly, 
revealed that MIM expression is nega­
tively correlated with the expression 
of these factors and that knockdown 
of expression of either CTTN or Src 
restored cilia formation and Shh signal­
ing in MIM knockdown cells. Overall, 
these studies demonstrated that modu­
lation of the actin cytoskeleton via 
MIM, Src, and CTTN provides a cell 
cycle–dependent switch for primary 
cilia assembly and disassembly.
In additional studies of the Shh sig­
naling pathway, Marina Grachtchouk 
(University of Michigan, Ann Arbor) 
described differences in the responsive­
ness of follicle stem cell compartments 
to oncogenic Shh signaling. Because 
uncontrolled Shh signaling activation 
contributes to tumorigenesis, this group 
activated the Shh pathway oncogene 
GLI2* using a conditional mouse model 
to test the tumorigenic potential of 
these activators targeted to hair follicle 
stem cells. Depilation, which triggers 
anagen hair growth in control animals, 
triggered widespread tumor develop­
ment in the GLI2* mice. The tumors, 
which derived from the hair follicles, 
expressed the Shh target genes Gli1 
and Ptch1. Although the transgene and 
target genes were expressed in both 
the bulge and the secondary hair germ 
(SHG), tumorigenesis was initiated only 
in the SHG of telogen hair follicles, 
suggesting that stem cells in different 
niches respond to signals differently.
Another critical factor for epithe­
lial development and differentiation is 
the p53 family member p63. Maranke 
Koster (University of Colorado, Denver) 
gave an in­depth account of her work 
on the role of p63 in skin develop­
ment and disease. In the absence of 
p63 expression, mice fail to develop 
epidermis or epithelial appendages, 
whereas ectopic p63 expression in 
lung epithelia induces epidermal dif­
ferentiation. Thus, this protein is clearly 
important in the initiation of epithelial 
development. Studies with the devel­
opment­inducible ∆Np63 knockdown 
mouse revealed an essential role for 
p63 in basement membrane formation, 
terminal differentiation, and barrier 
formation. Although aberrant expres­
sion of p63 occurs in skin cancers such 
as squamous cell carcinoma (SCC), 
this transcription factor is not mutated 
in these cells. In fact, expression of 
p63, typically the ∆Np63α isoform, in 
human SCCs indicates a good progno­
sis with low invasion/metastasis poten­
tial. These cancer cells also maintain 
differentiation, and tumor progres­
sion is inhibited. On the other hand, 
a poor prognosis with metastasis and 
a loss of differentiation is observed in 
the absence of p63 expression. Indeed, 
downregulation of ∆Np63α leads to 
spontaneous and more aggressive SCC 
tumors.
Because inherited p63 mutations 
have been identified in subsets of 
patients with ectodermal dysplasias 
(AEC, ankyloblepharon ectodermal 
dysplasia and clefting; EEC, ectro­
dactyly ectodermal dysplasia and 
clefting), which are characterized by 
differentially presenting developmental 
abnormalities in the skin and skin 
appendages, Dr. Koster has focused on 
understanding the role of this protein in 
these disease phenotypes. Apparently, 
different p63 target genes are affected 
by these mutations, giving rise to the 
various phenotypes. For example, in 
EEC patients, Dlx5/Dlx6 induction is 
compromised; however, these proteins 
are not affected in AEC mutants. In 
addition, Antonio Costanzo (University 
of Rome Tor Vergata, Italy) described 
the involvement of the p63 downstream 
target, interferon regulatory factor 
6 (IRF6), in ectodermal dysplasias. 
Mutation of IRF6 results in a phenotype 
similar to that of p63 mutation with 
developmental defects and epidermal 
hyperproliferation in mice. The ∆Np63 
isoform induces transcription of IRF6 
at the onset of terminal keratinocyte 
differentiation. AEC patients exhibit 
reduced IRF6 expression and increased 
p63 expression in the epidermis. Once 
induced by ∆Np63, IRF6 actually con­
trols ∆Np63 expression during kerati­
nocyte differentiation via induction of 
∆Np63 proteasome­mediated degrada­
tion. Thus, a regulatory feedback loop 
involving p63 and IRF6 links the patho­
genesis of two genetically distinct ecto­
dermal dysplasias.
Another player in the p63 signaling 
cascade is the special AT­rich binding 
protein Satb1. Although the molecu­
lar signatures of the epidermal layers 
are currently being elucidated, little is 
known about the three­dimensional 
chromatin organization and the dynam­
ics of tissue­specific gene expression. 
Vladimir Botchkarev (University of 
Bradford, UK; Boston University, MA) 
described the control of this chromatin 
organization by the genome organizer 
Satb1 during epidermal development. 
The central motif of Satb1 binds to the 
matrix attachment regions of DNA 
enriched with AT base pairs. This protein 
is expressed in basal epidermal kerati­
nocytes during skin development, and 
knockout of Satb1 results in a significant 
decrease in epidermal thickness and 
proliferation and alteration in the three­
dimensional structure of the central epi­
dermal differentiation complex (EDC) 
domain. Because Satb1 is decreased 
in the epidermis of p63−/− mice and is 
downregulated following p63 siRNA 
treatment, this protein is a key player in 
the p63­dependent program of tissue­
specific chromatin remodeling during 
epidermal development.
epidermal development
Although the complex regulation of the 
EDC affects epidermal differentiation, 
Christina de Guzman Strong (National 
Institutes of Health, Bethesda, MD) 
described the link of this locus to AD 
and psoriasis based on the discovery of 
mutations in filaggrin associated with 
AD and copy number variations within 
the LCE genes associated with psoria­
sis. Because the expression of genes in 
the EDC is coordinated by regulatory 
conserved noncoding elements (CNE), 
this group employed a comparative 
genomics approach to identify such 
elements. Using mammalian genomes 
ranging from humans to opossums, 48 
CNEs were identified as potential cis­
regulatory elements. These elements 
were confirmed in reporter assays in 
keratinocytes and in in vivo enhancer 
assays. Overall, these studies demon­
strated conserved coordinated regula­
tion of the EDC and epidermal­specific 
enhancer activity in vivo in two CNEs, 
including one that mapped within the 
psoriasis­associated locus.
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Single­layer to multilayer epidermal 
stratification occurs over the course of 
a few days during embryogenesis. To 
understand the mechanisms of asym­
metric cell division, which promote 
stratification and differentiation, Terry 
Lechler (Duke University, Durham, 
NC) examined how cells orient their 
spindles to determine whether to 
divide asymmetrically to generate 
suprabasal cells or symmetrically to 
increase surface area, a choice nearly 
all epidermal progenitor cells make. 
Inscuteable (Insc), a key regulator of 
spindle orientation in Drosophila, is 
specifically expressed in these cells. In 
transgenic mice with controlled expres­
sion of mInsc in the basal layer of the 
epidermis in mitotic cells, an increase 
in asymmetric divisions was observed, 
indicating that regulation of expression 
of this factor is critical for this decision. 
In addition to this regulatory control 
point, Dr. Lechler also described the 
colocalization of the nuclear mitotic 
apparatus protein, which tethers mitot­
ic spindles to the poles, with mInsc in 
asymmetrical but not symmetrical cell 
divisions, illuminating mechanisms of 
the decision process in mammalian 
epidermal stratification.
In an effort to isolate quiescent mel­
anocyte progenitors in a viable state 
to more clearly understand melano­
cyte differentiation, Thomas Hornyak 
(National Institutes of Health, Bethesda, 
MD) discussed a complementary tet­
racycline­regulated transgenic mouse 
system. Melanocyte label­retaining 
cells were localized to the bulge region 
in tet­off animals and the SHG in tet­
on animals. Interestingly, a hair follicle 
pigmentary reconstitution assay to test 
melanocyte stem cell function in vivo 
revealed that both bulge and SHG qui­
escent melanocytes were capable of 
regenerating the follicular pigmentary 
unit.
In a talk about the role of cad­
herins in normal and diseased skin, 
Carein Niessen (University of Cologne, 
Germany) described the classic cad­
herin–catenin complexes in adherens 
junctions that function in epithelial 
cell adhesion. Cadherins are required 
for coordinated movement and migra­
tion, sorting/positioning of cells, and 
the establishment and maintenance 
of polarity. Therefore, loss of cadherin 
function results in loss of tissue integ­
rity. Specifically, E­cadherin, which 
is expressed in the upper layers of the 
skin, functions in adhesion and barrier 
formation. Although loss of epidermal 
E­cadherin results in water loss via 
alterations in tight junctions, E­cadherin 
and protein kinase C together regulate 
a late step in tight junction barrier for­
mation. Normal desmosome formation, 
however, occurs in epidermis that lacks 
E­cadherin, although knockout of both 
E­cadherin and P­cadherin disrupts this 
structure. In addition, inhibition of epi­
dermal growth factor receptor signal­
ing restores the desmosomes in these 
knockout mice, suggesting a role of 
cadherins in the regulation of epider­
mal growth factor receptor signaling. 
Together, these studies indicated that 
differential cadherin levels determine 
skin barrier function and integrity: low 
levels allow desmosome formation, 
and higher levels result in functional 
tight junction formation. Importantly, 
cadherins have been implicated in skin 
diseases that are characterized by barri­
er dysfunction, inflammation, and auto­
immunity, as well as in skin cancer.
pemphigus pathogenesis
In the Albert Kligman/Phillip Frost 
Leadership Lecture, which is awarded 
in acknowledgment of significant con­
tributions to the understanding of the 
structure and function of the skin, John 
Stanley (University of Pennsylvania, 
Philadelphia) described the personal 
and scientific lessons he’s learned dur­
ing his studies of pemphigus. Both 
informative and entertaining, Dr. 
Stanley recounted the experiences 
gained in his research career, advising 
young researchers to become obsessed 
with research, enjoy the process of sci­
ence, collaborate, and embrace new 
technology.
Furthering the discussion on this 
blistering disease, Masayuki Amagai 
(Keio University, Tokyo, Japan) dis­
cussed pemphigus vulgaris (PV) as a 
paradigm of autoimmune disease. PV 
is mediated by IgG autoantibodies 
directed against desmoglein 3 (Dsg3). 
Autoimmunity occurs when tolerance, 
which is the failure to respond to an 
antigen (especially a self­antigen), is 
faulty. Although T cells are thought to 
be the commander­in­chief behind PV 
because of their key role in autoanti­
body production, passive transfer of 
IgG autoantibodies, but not T cells, 
results in blistering in neonatal mice. 
Development of a Dsg3 T­cell receptor 
(TCR) transgenic mouse model provid­
ed a tool for the analysis of central and 
peripheral tolerance. Autoimmunity 
regulator, which promotes self­tol­
erance by inducing transcription of 
tissue­specific antigens, is essential for 
expression of Dsg3 in medullary thy­
mic epithelial cells. Adoptive transfer 
of the Dsg3­specific transgenic T cells, 
as well as retroviral transduction of 
Dsg3­specfic TCR on peripheral CD4+ 
T cells, induced interface dermatitis. 
Furthermore, the transgenic T cells 
that developed in the absence of Dsg3 
induced not only anti­Dsg3 IgG pro­
duction but also T­cell infiltration in 
vivo. Thus, this mouse model provides 
a mechanism to study the pathophysi­
ological mechanisms underlying pem­
phigus.
Analysis of the molecular events 
involved in PV pathogenesis by Xuming 
Mao (University of Pennsylvania, 
Philadelphia) revealed that p38α mito­
gen­activated protein kinase (MAPK) 
is not required for the loss of intercel­
lular adhesion that characterizes this 
disease. Because p38 MAPK activation, 
which occurs in response to proinflam­
matory cytokines and cellular stress, 
has been detected in PV patient skin 
samples, this group investigated the 
role of this kinase in the pathogenesis 
of PV. Pathogenic antibodies against 
Dsg3 induced endocytosis of Dsg3 and 
loss from the desmosome. Some but 
not all of the pathogenic PV antibodies 
activated p38 MAPK, and this activa­
tion was secondary to blister formation. 
In mice with an epidermal deletion of 
p38α MAPK, Dsg3 internalization by 
the pathogenic antibodies was inhibit­
ed, although the antibodies still caused 
loss of intercellular adhesion. Using a 
complementary approach, these inves­
tigators demonstrated that inhibition of 
p38 MAPK expression via RNA interfer­
ence prevented the internalization and 
loss of desmosomal Dsg3. These results 
illustrate that genetics can modify as 
well as cause disease.
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translational medicine
Effective wound healing occurs through 
a highly regulated multistage process 
that involves multiple cell types. Liora 
Braiman­Wiksman (HealOr Ltd., Ness 
Ziona, Israel) presented her findings on 
adipocytes and adiponectin secretion in 
skin physiology and wound healing in 
diabetic skin. Subcutaneous adipocytes 
participate in the wound healing pro­
cess; however, adipocyte morphology 
is impaired in diabetic skin, rendering 
the wound healing process defective. 
Adiponectin, which exhibits inflam­
matory properties, is secreted from 
adipocytes, albeit at reduced levels in 
type 2 diabetic patients. This factor is 
induced during normal wound healing 
and is recruited to the wound following 
secretion from blood vessels. Treatment 
of wounds in mice with adiponectin 
promoted dermal closure. Indeed, 60% 
of the wounds treated with this protein 
exhibited epidermal closure, whereas 
only 30% of the untreated wounds 
did. In addition, significant inflamma­
tion was detected in the wounds even 
after 7 days; however, treatment with 
adiponectin significantly reduced the 
percentage of inflamed wounds. Thus, 
adiponectin is a promising therapeutic 
candidate for the treatment of diabetic 
wounds.
Melanoma, actinic keratosis along 
with squamous cell carcinoma and 
basal cell carcinoma, and photoaging 
have all been linked to solar UV radia­
tion exposure. Evaluation of sunscreen 
particles is particularly important in 
infants and young children, because 
exposure to UV at a young age is of 
particular concern. M. Catherine Mack 
(Johnson & Johnson Consumer Products 
Worldwide, Skillman, NJ) presented 
studies on the penetration of micron­
ized sunscreen particles. Although 
accumulating evidence indicates that 
sunscreen particles do not penetrate 
through the intact stratum corneum in 
animals and adults, the epidermal bar­
rier is still developing in infants; thus, 
results from studies in adults cannot 
be directly applied to infants. Using 
Raman confocal microspectroscopy 
and/or confocal laser scanning micros­
copy, these investigators found that 
neither titanium dioxide nor zinc oxide 
particles penetrated deeper than the 
first few layers of the stratum corneum. 
These particles were not detected in the 
deeper layers in adults or infants, indi­
cating that these micronized sunscreen 
particles remain safely on the skin sur­
face to deflect UV radiation.
In another plenary session presenta­
tion, Eleni Linos (Stanford University, 
Palo Alto, CA) described studies of life­
time UV exposure and risk for lentigo 
maligna melanoma (LMM). Although 
meta­analyses show no impact of 
chronic sun exposure on melanoma, 
intermittent exposure early in life pre­
dicts melanoma. Because LMM occurs 
on chronically sun­exposed sites, the 
effects of lifetime UV exposure on inci­
dent LMM were examined in 121,000 
female nurses and 51,000 male health 
professionals. Although no effects on 
non­LMM were observed, significant 
effects were observed for LMM. A 
37% increase in LMM was found for 
those born in high­UV index regions, 
with a 56% greater lifetime risk of 
LMM if the individual remained in 
the high­UV exposure area. The mag­
nitude of these effects was similar to 
that observed for other photosensitive 
cancers, supporting the effects of UV 
exposure in LMM risk.
In the Eugene M. Farber Lecture, 
which is presented to an investigator 
whose work is relevant to expanding 
our insights into the patho physiology 
and treatment of psoriasis, James 
Krueger (The Rockefeller University, 
New York, NY) discussed the path of 
translational medicine for this chronic 
inflammatory disease. Indeed, transla­
tional medicine is a scientific process 
that begins with the elucidation of the 
underlying pathogenesis of a disease 
and then seeks to bring novel effective 
treatments to patients in need. In this 
informative “bench­to­bedside” talk, 
Dr. Krueger described the history of 
psoriasis treatments from the early IL­2 
fusion protein in 1995 to alefacept in 
2001 and efalizumab and etanercept 
in 2004. Understanding how inflam­
mation is involved in the epithelial 
cell proliferative response has been the 
focus of considerable research. Because 
disease reversal has recently been 
observed following treatment with the 
IL­17 receptor agonist, targeting psoria­
sis with selective immunosuppressive 
drugs may offer an effective treatment 
strategy. In addition, Dr. Krueger’s 
group has identified a significant 
molecular gene expression remnant in 
resolved lesions following treatment 
with etanercept or ustekinumab, under­
scoring the complexity of the etiology 
of this disease and the challenges for 
treatment. As with all stories about 
incurable diseases, the quest for the 
perfect treatment is still underway; 
however, Dr. Krueger and others have 
made remarkable advances in under­
standing not only the cellular players 
and pathways involved in this disease 
process but also the genetic signature 
of the disease.
In the William Montagna Lecture, 
which is an award presented to a young 
active investigator who is making a 
contribution in the field of skin biol­
ogy, W.H. Irwin McLean (University 
of Dundee, Scotland, UK) chronicled 
his work on inherited skin diseases. 
Mutation of keratins, which are inter­
mediate filament proteins, results in 
cell fragility and over­ or undergrowth. 
The first clinical trials for siRNA in 
human skin were conducted with 
molecules to knock out the dominant 
negative mutant keratin 6a allele of 
pachyonychia congenita. This treat­
ment eliminated the phenotype in cells 
and effectively decreased callus forma­
tion, essentially opening up this avenue 
for treatment of other skin diseases. 
Furthermore, McLean’s group has iden­
tified small molecules to target these 
mutations as well. As a result, ongoing 
studies with combination therapy with 
statins and low­dose retinoids offer 
promising results. Recently, filaggrin 
null mutations that result in defec­
tive keratin aggregation and defective 
epidermal barrier function have been 
implicated in ichthyosis vulgaris, AD, 
and asthma, and these defects allow 
pathogens to gain access and trigger an 
immune response, inflammation, and 
eczema. Development of new therapies 
from genetics and the recent genome­
wide association studies has been dis­
appointing; however, high­throughput 
screening for siRNA and small mole­
cule drugs has been rewarding. In addi­
tion, gene–environment interactions 
appear to modify this disease, as evi­
denced by work in filaggrin­deficient 
Yarnall Schultz
Scientific Highlights from the Society for Investigative Dermatology 2010 Annual Meeting
 www.jidonline.org 2165
mice. Importantly, the recent identifi­
cation and subsequent investigation of 
filaggrin in AD has drawn considerable 
attention to the importance of keratino­
cytes and the epidermal barrier.
immunology
Because many of the diseases affecting 
the skin involve inflammatory media­
tors, understanding the immunological 
response is critical for elucidating dis­
ease mechanisms. Akiharu Kubo (Keio 
University, Tokyo, Japan) presented 
data demonstrating that Langerhans 
cell dendrites penetrate through the 
epidermal tight junction barrier dur­
ing foreign antigen uptake. Although 
tight junctions limit paracellular leak­
age in epithelial cellular sheets, acti­
vated Langerhans cells, which typically 
remain under the tight junction barrier, 
elongate their dendrites through this 
barrier to uptake antigens in a type of 
surface surveillance system in both 
mice and humans.
Furthermore, Kurt Lu (Case Western 
Reserve University, Cleveland, OH) 
presented his research on skin inflam­
mation and wound healing. In IL­6 
knockout mice, wound healing is mild­
ly delayed, and treatment of these mice 
with a peroxisome proliferator–activat­
ed receptor­γ (PPARγ) agonist has no 
effect. Tissue destruction and severe 
delayed wound healing, however, was 
observed following UVB and PPARγ 
treatment. The wound tissue was also 
infiltrated by macrophages. Inducible 
nitric oxide synthase (iNOS), a proin­
flammatory player, was upregulated 
in the experimental wounds in IL­6 
knockout mice. In fact, blocking iNOS 
blocked wound tissue destruction in 
these mice. Thus, generation of hyper­
inducible nitric oxide synthase­express­
ing macrophages leads to a severe delay 
in wound healing. Because therapeutic 
anti­IL­6 biologics have been approved 
for treatment of rheumatoid arthritis and 
autoantibody­mediated IL­6 deficiency 
is often observed in type 2 diabetes, 
these results have clinical relevance 
beyond this wound healing model.
In a description of yet another 
subset of immune cells in the skin, 
Thomas Kupper (Brigham and Women’s 
Hospital, Boston, MA) discussed his 
work on effector memory T (TEM) cells 
in the skin. Surprisingly, the skin har­
bors more than twice as many T cells as 
the blood, and almost all of these are 
TEM. Vaccination of mice via skin scari­
fication with live Vaccinia virus (VACV) 
that was genetically engineered to 
express the OT­1 TCR allowed scientists 
to study the temporal behavior of the 
TEM. Specific T cells were detected very 
early after infection prior to migration 
to the draining lymph nodes and other 
lymphoid tissues before reaching the 
skin. The viral antigen­specific CD8+ 
TEM produced proinflammatory cyto­
kines upon activation and protected 
against reinfection through peripheral 
tissues. Overall, these TEM were found 
to persist long term in the skin to pro­
vide immunity, and their recirculation 
into the blood was limited.
Viruses and vaccines
In addition to presentations of research 
directly relating to the skin or skin dis­
eases, the Herman Beerman Lecture, 
which features a renowned medical 
scholar from a field outside of derma­
tology, was presented by Raymond 
Schinazi (VA Medical Center/Emory 
University, Atlanta, GA), who discussed 
the changing landscape of HIV and 
hepatitis C virus (HCV) therapies. With 
25 reagents available for treatment 
(some pioneered at Emory University), 
HIV has a 94% survival rate as of 2008. 
Unfortunately, up to one­third of HIV­
infected individuals are co­infected 
with HCV, a situation that is more com­
plicated and more difficult to treat. 
Based on the success of the 1 of 10,000 
new drugs that makes it to market, 
researchers have found that targeting 
host factors in combination with viral 
factors is useful, that toxicity must be 
minimized as side effects prove prob­
lematic, that resistance is a prominent 
theme with these drug treatment pro­
tocols, and that combination regimes 
must be studied early to maximize 
potential treatment. On a final note, 
Dr. Schinazi emphasized that although 
great strides have been made in the 
development of therapeutics for HIV 
and HCV, success should be measured 
in number of lives saved as opposed to 
dollars generated.
Furthering the discussion of treating 
chronic viral infections, Rafi Ahmed 
(Emory University, Atlanta, GA) pre­
sented the Julius Stone Lecture, which 
is given to promote the advancement of 
knowledge in immunology as it relates 
to the skin and skin disease. Gene pro­
filing of memory T cells that often are 
functionally exhausted during chronic 
HCV infection revealed overexpres­
sion of several inhibitory receptors, 
including the coinhibitory programmed 
death­1 (PD­1). Binding of PD­1 
ligand (PD­L1) to the highly expressed 
PD­1 on T cells during chronic infec­
tion causes a lack of function of these 
cells. Although therapeutic vaccination 
based on this pathway was unsuccess­
ful, therapeutic vaccination combined 
with PD­L1 blockade increased the 
T­cell response with greater numbers 
of CD8+ T cells. This strategy has been 
applied with good results in the labora­
tory for simian immunodeficiency virus 
in monkeys, and increased levels of 
PD1 and PD­L1 expression have been 
noted in liver T cells in HCV patients. 
This therapy appears to be promising 
not only for chronic viral infections but 
also in the treatment of tumors.
In the Naomi M. Kanof Lecture, 
which was established to honor an 
individual making significant contri­
butions to the improvement of health 
through clinical research, Douglas 
Lowy (National Institutes of Health, 
Bethesda, MD) described current and 
future preventive human papilloma­
virus (HPV) vaccines. HPV has served 
as the poster child for a cancer­causing 
virus. In fact, this HPV­induced cervi­
cal cancer is the second most common 
cause of death from cancer in women 
worldwide. The currently approved 
commercial HPV vaccines (Cervarix 
from GlaxoSmithKline and Gardasil 
from Merck) are L1 virus­like particles 
that exhibit high protection against 
genital warts and dysplasia in three 
animal models as well as in fully vac­
cinated women. The immune response 
involves the generation of high­titer 
antibodies that prevent viral basement 
membrane binding. Although the vac­
cine is highly effective, 30% of HPV 
infections and cancers are not pro­
tected, and the vaccine is not effec­
tive against established lesions. One 
potential improvement to this strategy 
involves the addition of multiple HPV 
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types to the vaccine. L2 polypeptides 
are candidates for incorporation into 
a vaccine because this minor capsid 
protein contains cross­neutralization 
epitopes, which are cryptic and thus 
only exposed during infection. This 
approach offers the chance for a pan­
HPV vaccine, although no success­
ful vaccine with cryptic epitopes has 
been developed. Fortuitously, L2 cross­
neutralization epitopes are exposed 
while the virus is bound to the base­
ment membrane but before the virus 
transfers to the keratinocytes. This life 
cycle feature allows induced neutral­
izing antibodies a chance to prevent 
infection. To date, L2 vaccine confers 
broad­spectrum protection from HPV 
challenge even against strains not 
included in the vaccine. In addition, in 
vivo neutralizing L2 antibodies cause 
HPV16 capsid displacement from the 
basement membrane, supporting the 
use of this strategy in the development 
of a new generation of HPV vaccines.
Conclusion
Overall, the annual meeting of the 
Society for Investigative Dermatology 
achieved its goals of reaching all mem­
bers of the dermatology and cutaneous 
biology research communities. With the 
research presentations and associated 
meetings and symposia, basic scien­
tists, clinicians, students, residents, and 
postdocs were offered a glimpse into 
the current state of top­notch dermato­
logical research. In addition, the mixing 
of multiple disciplines and researchers 
from various locations and career paths 
will foster information exchange and 
collaboration, which can only improve 
the science, both basic and clinical.
*The 70th Annual Meeting of the Society for 
Investigative Dermatology was held at the 
Hilton Atlanta Hotel, Atlanta, Georgia, on 5–8 
May 2010.
